Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (DE:1HM)
FRANKFURT:1HM
RESEARCH TOOLSreports
Holding DE:1HM?
Track your performance easily
1HM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.15 - €4.96
Previous Close€4.71
Volume0.00
Average Volume (3M)271.00
Market Cap
€707.53M
Enterprise Value€647.62M
Total Cash (Recent Filing)$291.88M
Total Debt (Recent Filing)$226.26M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 07, 2024EPS Estimate
-€0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding147,472,201
10 Day Avg. Volume3
30 Day Avg. Volume271
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.87
Price to Sales (P/S)4.59
Price to Cash Flow (P/CF)-11.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.84
Enterprise Value/Gross Profit6.84
Enterprise Value/Ebitda-4.81
Forecast
1Y Price Target
€6.76Price Target Upside43.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Adaptive Biotechnologies News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADPT pre-announced 1Q revenues above the Street, indicating stronger than expected financial performance.
Market LeadershipADPT owns the blood-based MRD testing space in the clinic and with pharma, and is a valuable strategic asset in the market.
Regulatory DevelopmentThe FDA's ODAC voted in favor of utilizing MRD as a primary endpoint for accelerated approval of therapies, which is a positive regulatory development for the company.
Bears Say
Earnings ReportADPT reported a Q4 top-line miss with revenue of $45.8M, a decline of 17% year-over-year.
Executive MovementCFO Tycho Peterson to depart for another opportunity, to be succeeded by ADPT's current Principal Accounting Officer, Kyle Piskel.
Financial PerformanceIM revenues declined by -43% year-over-year, reflecting decreased amortization and a strategic shift towards target and drug discovery.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.18% Insiders
13.81% Mutual Funds
0.21% Other Institutional Investors
62.19% Public Companies and
Individual Investors
1HM FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was €2.15 and its highest was €4.96 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Currently, no data Available
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Nov 07, 2024 which is in 28 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Aug 01, 2024. The company reported -€0.282 earnings per share for the quarter, beating the consensus estimate of -€0.304 by €0.022.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -€0.26.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 147,472,200 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -€0.282 in its last earnings report, beating expectations of -€0.304. Following the earnings report the stock price went down -2.769%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Among the largest hedge funds holding Adaptive Biotechnologies Corp’s share is Viking Global Investors LP. It holds Adaptive Biotechnologies Corp’s shares valued at 109M.
---
Adaptive Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.76 (43.67% Upside)
€6.76 (43.67% Upside)
Blogger Sentiment
Neutral
DE:1HM Sentiment 50%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.99%
12-Months-Change
Fundamentals
Return on Equity
-66.96%
Trailing 12-Months
Asset Growth
-23.50%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
---
1HM Company Deck
---
1HM Earnings Call
Q2 2024
0:00 / 0:00
---
1HM Stock 12 Month Forecast
Average Price Target
€6.76
▲(43.67% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Guardant Health
―
Twist Bioscience
―
Quanterix
―
10x Genomics
―
Best Analysts Covering 1HM
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-7.38%
reiterated a buy rating 14 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.38% per trade.
---